Deep learning radiopathomics predicts targeted therapy sensitivity in EGFR-mutant lung adenocarcinoma
Open Access
- 29 April 2025
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-12
Abstract
Ttyrosine kinase inhibitors (TKIs) represent the standard first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, not all patients with EGFR mutations respond to TKIs. This study aims to develop a deep learning radiological-pathological-clinical (DLRPC) model that integrates computed tomography (CT) images, hematoxylin and eosin (H&E)-stained aspiration biopsy samples, and clinical data to predict the response in EGFR-mutant lung adenocarcinoma patients undergoing TKIs treatment. We retrospectively analyzed data from 214 lung adenocarcinoma patients who received TKIs treatment from two medical centers between September 2013 and June 2023. The DLRPC model leverages paired CT, pathological images and clinical data, incorporating a clinical-based attention mask to further explore the cross-modality associations. To evaluate its diagnostic performance, we compared the DLRPC model against single-modality models and a decision level fusion model based on Dempster-Shafer theory. Model performances metrics, including area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were used for evaluation. The Delong test assessed statistically significantly differences in AUC among models. The DLRPC model demonstrated strong performance, achieving an AUC value of 0.8424. It outperformed the single-modality models (AUC = 0.6894, 0.7753, 0.8052 for CT model, pathology model and clinical model, respectively. P < 0.05). Additionally, the DLRPC model surpassed the decision level fusion model (AUC = 0.8132, P < 0.05). The DLRPC model effectively predicts the response of EGFR-mutant lung adenocarcinoma patients to TKIs, providing a promising tool for personalized treatment decisions in lung cancer management.Keywords
Funding Information
- Chongqing Municipal Key Laboratory of Signal and Information Processing (No.2023ZDXM008)
- Centre of Excellence and Applied Sport Science Research, Queensland Academy of Sport (No. YYKYXM202303B05)
This publication has 40 references indexed in Scilit:
- Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non–Small Cell Lung Cancer From Hematoxylin and Eosin–Stained Slides Using Deep LearningLaboratory Investigation, 2024
- Hematoma expansion prediction: still navigating the intersection of deep learning and radiomicsEuropean Radiology, 2024
- Computerized tertiary lymphoid structures density on H&E-images is a prognostic biomarker in resectable lung adenocarcinomaiScience, 2023
- Standardized Classification of Lung Adenocarcinoma Subtypes and Improvement of Grading Assessment Through Deep LearningThe American Journal of Pathology, 2023
- Deep learning radiopathomics based on preoperative US images and biopsy whole slide images can distinguish between luminal and non-luminal tumors in early-stage breast cancersEBioMedicine, 2023
- Improved breast cancer histological grading using deep learningAnnals of Oncology, 2022
- Emerging role of deep learning‐based artificial intelligence in tumor pathologyCancer Communications, 2020
- Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesCell Metabolism, 2018
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Support-vector networksMachine Learning, 1995